IACS-010759 is primarily investigated for its potential in cancer therapy, particularly in targeting cancer cells with specific metabolic dependencies. It functions as a potent inhibitor of mitochondrial complex I, which is crucial for cellular energy production. By disrupting this pathway, IACS-010759 effectively starves cancer cells of the energy they need to proliferate, making it a promising candidate for treating cancers that rely heavily on oxidative phosphorylation, such as acute myeloid leukemia (AML) and certain solid tumors. Its application is being explored in preclinical and clinical studies to assess its efficacy and safety in inhibiting tumor growth and improving patient outcomes.